[1] Villanueva A. Hepatocellular Carcinoma. N Engl J Med,2019,380(15): 1450-1462.
[2] Nan Y, An J, Bao J, et al. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. J Hepatol,2021,75(2): 454-461.
[3] Kyi C, Postow MA. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy,2016,8(7): 821-837.
[4] Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med,2008,359(4): 378-390.
[5] Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol,2018,15(10): 599-616.
[6] Sangro B, Melero I, Wadhawan S, et al. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol, 2020,73(6): 1460-1469.
[7] Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol,2018,19(7): 940-952.
[8] Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med,2020,382(20): 1894-1905.
[9] Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol,2020,72(2): 215-229.
[10] Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology,2017,153(3): 812-826.
[11] Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature, 2017,541(7637): 321-330.
[12] Li F, Li C, Cai X, et al. The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis. EClinicalMedicine,2021,41: 101134.
[13] Lu S, Stein JE, Rimm DL, et al. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. JAMA Oncol, 2019, 5(8): 1195-1204.
[14] Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature,2021,592(7854): 450-456.
[15] Murai H, Kodama T, Maesaka K, et al. Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma. Hepatology,2023,77(1): 77-91.
[16] Chiang DY, Villanueva A, Hoshida Y, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res,2008,68(16): 6779-6788.
[17] Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res, 2009, 69(18): 7385-92.
[18] Quigley M, Pereyra F, Nilsson B, et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med,2010,16(10): 1147-1151.
[19] Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun,2013,4: 2612.
[20] Thommen DS, Schumacher TN. T Cell Dysfunction in Cancer. Cancer Cell,2018, 33(4): 547-562.
[21] Stephen TL, Rutkowski MR, Allegrezza MJ, et al. Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. Immunity, 2014,41(3): 427-439.
[22] Cassidy FH, Yokoo T, Aganovic L, et al. Fatty liver disease: MR imaging techniques for the detection and quantification of liver steatosis. Radiographics,2009,29(1): 231-260. |
